

Supplementary Table 2. Characteristics of the 305 women with breast cancer who developed secondary malignant neoplasms and of 1,525 matched controls

Characteristic	Case (n=305) No. (%)	Matched (n=1,525) No. (%)	Characteristic	Case (n=305) No. (%)	Matched (n=1,525) No. (%)
Median age at diagnosis of BC (yr)	64 (31-88)	64 (27-93)	HER2		
Age at diagnosis of BC (yr)			Negative	115 (37.7)	633 (41.5)
<50	39 (12.8)	195 (12.8)	Positive	32 (10.5)	102 (6.7)
50-59	71 (23.3)	355 (23.3)	Unknown	158 (51.8)	790 (51.8)
60-70	103 (33.7)	515 (33.7)	Genetic predisposition		
>70	92 (30.2)	460 (30.2)	Sporadic	277 (90.8)	1,403 (92.0)
Year of diagnosis of BC			Familial*	19 (6.2)	95 (6.3)
1996-1998	133 (43.6)	665 (43.6)	Inheritance [†]	7 (2.4)	12 (0.7)
1999-2001	92 (30.2)	460 (30.2)	Unknown	2 (0.6)	15 (1.0)
2002-2004	64 (21.0)	320 (21.0)	Menopausal status [‡]		
2005-2007	16 (5.2)	80 (5.2)	Premenopausal	52 (17.0)	239 (15.7)
Stage of BC			Postmenopausal	253 (83.0)	1,286 (84.3)
IA-IIIB	261 (85.6)	1,305 (85.6)	Interval to second malignancies (yr)		
IIIA-IV	44 (14.4)	220 (14.4)	1-3	123 (40.0)	
Grading			4-7	116 (38.0)	
1/2	184 (60.3)	968 (63.5)	7-11	66 (22.0)	
3	112 (36.7)	500 (32.8)	Histological type		
Unknown	9 (3.0)	57 (3.7)	Infiltrating duct carcinomas	246 (80.6)	1,177 (77.2)
Primary tumor size (T)			Infiltrating lobular mixed	33 (10.8)	218 (14.3)
T mic-T1b	101 (33.1)	471 (30.9)	Mucinous adenocarcinoma	9 (3.0)	46 (3.0)
T1c	119 (39.0)	646 (42.4)	Tubular adenocarcinoma	8 (2.6)	27 (1.8)
T2	71 (23.3)	353 (23.1)	Other	9 (3.0)	57 (3.7)
Unknown	14 (4.6)	55 (3.6)	Treatment		
Estrogen receptors (%)			Surgery alone	28 (9.2)	116 (7.6)
≥10	233 (76.4)	1,212 (79.5)	Surgery+CHT	22 (7.2)	69 (4.5)
<10	62 (20.3)	269 (17.6)	Surgery+RT	37 (12.1)	137 (9.0)
Unknown	10 (3.3)	44 (2.9)	Surgery+CHT+RT	24 (7.9)	102 (6.7)
Progesterone receptors (%)			Surgery+HT	47 (15.4)	253 (16.6)
≥10	193 (63.3)	954 (62.5)	Surgery+HT+CHT	23 (7.5)	150 (9.8)
<10	101 (33.1)	524 (34.4)	Surgery+HT+RT	78 (25.6)	398 (26.1)
Unknown	11 (3.6)	47 (3.1)	Surgery+HT+CHT+RT	46 (15.1)	301 (19.7)
Ki-67 (%)					
<20	185 (60.7)	969 (63.5)			
≥20	108 (35.4)	488 (32.0)			
Unknown	12 (3.9)	68 (4.5)			

The case-control ratio was 1:5.

BC=breast cancer; FIGO=International Federation of Gynecologic and Obstetric; HER2=human epidermal growth factor receptor 2; CHT=chemotherapy; RT=radiotherapy; HT=homonotherapy.

*The woman have at least two first-degree relatives (mother, father, daughter, son, sister, brother) with breast cancer disease; [†]Mutation of breast cancer gene (*BRCA1* or *BRCA2*); [‡]Premenopausal: age ≤50 years, postmenopausal: age >50 years.